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Summary
Small noncoding RNAs (snRNAs) were discovered more
than two decades ago, yet it was not until relatively re-
cently that their important role in genome regulation was
recognised. With such a substantial role in genome regula-
tion, it is not surprising that snRNAs are crucial contribut-
ors to an ever-increasing number of diseases, as evidenced
by the long list of published studies. Currently, microRNAs
(miRNAs) represent the most intensively studied snRNAs.
Dysregulation of miRNAs has been confirmed in numer-
ous diseases, and changes in their levels could play an es-
sential role in disease onset and progression and could be
used for prognosis and potential therapy. Indeed, disease-
altered miRNAs may either signify a direct trigger or a
consequence of the disease. Therefore, miRNAs represent
unique targets for disease intervention through their down-
or up-regulation. Importantly, miRNAs may facilitate dis-
ease monitoring by detection of disease-altered miRNAs
in easily accessible bodily fluids, such as blood or
cerebrospinal fluid. Therefore, study of these events is of
utmost importance for understanding the molecular mech-
anisms that drive disease, as well as for diagnosis and
therapy. Here we attempted to synthesise a large number
of studies to highlight the crucial role of miRNAs in the
pathogenesis of neurodegenerative, muscle, cardiovascular
and inflammatory diseases.
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Introduction
While the incredible race to sequence the human genome
was in progress, it was predicted and anticipated that hu-
mans would have more protein-coding genes than, for in-
stance, the mouse [1, 2]. The results were therefore quite
surprising, since only about 1%–2% of the human DNA is
‘coding’ [3]. The rest was given names such as ‘noncoding’
or ‘junk’ DNA and it was not until relatively recently that
the majority of this ‘junk DNA’ was acknowledged to be
transcribed [4–6] and to have a function [7]: indeed, a func-
tion that has changed our view of gene expression, genome
regulation and even evolution, development and the ever-
fascinating complexity of the brain and its rapid expansion
in primates [8, 9].
The first findings came about 20 years ago, when miRNA
in Caenorhabditis elegans was found to regulate gene ex-
pression or, more precisely, messenger RNA (mRNA)
translation [10]. The miRNAs were the first genome reg-
ulatory small noncoding RNAs to be discovered and since
then, various noncoding RNA species with multiple func-
tions have been identified [7].
Small noncoding RNAs (snRNAs) are present during evol-
ution, and the more complex the organism, the more spe-
cies of snRNAs develop (such as small interfering RNAs
[siRNAs], piwi-interacting RNA [piRNAs] and miRNAs).
It is believed that they originally served as genome pro-
tectors against endogenous and exogenous threats and that
they acquired their genome regulatory functions later in
evolution [8]. Long noncoding RNAs (lncRNAs) arrived
on the scene of gene regulation relatively recently but their
function appears to be connected to increased evolutionary
speed [8, 9]. The lncRNAs retain many of the protein-cod-
ing gene characteristics but are expressed with tighter tis-
sue specificity and are mainly nuclear localised [3]. These
differences indicate their function, as a new regulatory lay-
er responsible for fine-tuning the snRNAs [8] as demon-
strated by the numerous interactions between lncRNAs and
miRNAs [11–13].
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Box 1
Main enzymes of the miRNA pathway
Drosha – Enzyme that cleaves long primary pri-miRNA
transcripts generating approx. 70bp pre-miRNAs
Dicer – Enzyme that cleaves double-stranded RNA and
pre-miRNA into short double-stranded siRNAs and
miRNAs
RISC – RNA-induced silencing complex, a
multiprotein complex that incorporates one strand of
either siRNA or miRNA which then serves as a
template for perfect mRNA binding in case of siRNAs
or for binding to imperfect complementary sites within
the 3’UTRs of miRNA target mRNAs
Argonaute – Member of RISC, an enzyme that cleaves
the target mRNA leading to RNA interference by
mRNA degradation
Among the noncoding RNAs (ncRNAs), miRNAs are the
most extensively studied and over 2 000 miRNAs have so
far been identified in humans, each having several hun-
dreds of potential target mRNAs [14]. In addition, thou-
sands of single nucleotide polymorphisms (SNPs) were
discovered within miRNA sites [15] and length and se-
quence heterogeneity (IsomiRs) for the vast majority of
miRNAs has also been found [16]. Such polymorphisms
might therefore contribute to phenotypic differences or
even human diseases [15, 17, 18]. With such an extensive
involvement in gene regulation, it is of no surprise that
malfunctions of noncoding RNAs have been found to be
directly responsible for or contribute to the pathogenesis
of numerous disorders [8, 9, 17, 19]. These disease-indu-
cing changes could be used for diagnosis, as alterations
in miRNAs could be detected in cerebrospinal fluid or
even blood plasma [17]. Moreover, they could be used as
therapeutic targets [20, 21] with high potential, as a single
miRNA could have hundreds of targets [14]. Furthermore,
a major technological advancement originating from the
noncoding RNA field is the broadly used downregulation
of gene(s) of interest via small interfering RNA mechan-
ism. In conclusion, noncoding RNA research is gaining
momentum and we anticipate that while uncovering the
ncRNA interactions with DNA, RNA and proteins, we will
witness numerous, as yet unexplained, mechanisms becom-
ing the solutions for many diseases.
Here, we review the latest discoveries on the role of
miRNAs in human disease, focusing on neurodegenerative
diseases, skeletal muscle and cardiovascular diseases, and
the pathogenesis of inflammation.
Small noncoding RNAs in
neurodegenerative diseases
Since the hallmark of most neurodegenerative diseases is
protein aggregation [22], research has mainly been focused
on the study of these misfolded and aggregated protein
species. Hence, the term ‘proteinopathies’ has been es-
tablished. Recent discoveries, however, show that major
neurodegenerative diseases also involve miRNA dysfunc-
tion (table 1). Their importance for brain development and
function was first noted in Dicer knockout experiments,
resulting in absence of mature miRNAs and siRNAs, which
led to widespread neuronal alterations during development.
Dicer knockout is embryonically lethal in mice [23] and its
conditional inactivation in defined neuronal populations or
brain regions results in an abnormal phenotype and neuron-
al degeneration [24, 25]. Moreover, cell-specific Dicer ab-
lation in oligodendrocytes [25] or astrocytes [26] severely
affected miRNA biogenesis in these cells leading to their
malfunction, which ultimately resulted in noncell autonom-
ous neuronal dysfunction and degeneration, emphasising
the role of both miRNAs and glial cells in neurodegener-
ation. Further work revealed the involvement of miRNA
and siRNA in neuronal stem cell differentiation, cell-to-cell
interaction, neural development, axonal growth and guid-
ance, as well as synaptic transport [19, 26, 27]. Moreover,
piwi-interacting RNAs (piRNAs) and small-nucleolar
RNAs (snoRNAs) were shown to contribute in the regula-
tion of complex neuronal functions, such as learning and
memory formation [15, 28, 29].
Although the links between the dysregulated miRNAs in
neurodegenerative diseases and their target mRNAs or
their regulatory lncRNAs are still poorly understood, new
exciting discoveries highlight the role of miRNAs in the
pathogenesis of neurodegenerative diseases (fig. 1). Im-
portantly, miRNAs reflecting the disease stage have been
identified in plasma and whole blood samples, indicating
their potential use as biomarkers that are desperately
needed. In addition, given the large number and high stabil-
ity of circulating miRNAs, it is possible that through use of
unbiased high-throughput screenings, miRNAs could also
be used to differentiate neurodegenerative diseases from
other conditions, e.g., inflammatory neurological diseases.
In the following sections, we describe the role of the most
important miRNAs involved in Alzheimer’s disease, Par-
kinson’s disease, prion disease, amyotrophic lateral scler-
osis, frontotemporal dementia and Huntington’s disease.
Box 2
Staging of neurodegenerative diseases
Braak stages – AD staging that is based on the
distribution of tau neurofibrillary tangles (Braak I-VI).
Braak staging was also developed for PD where it is
based on distribution of Lewy bodies
HD grades – HD or Vonsattel grades are used for HD
staging and are based on the severity and pattern of
striatal degeneration (HD 0-4)
Alzheimer’s disease
Alzheimer’s disease (AD) is an age-related progressive de-
mentia and is the most common neurodegenerative disease.
With a worldwide prevalence estimated to be 24 million
[31], AD is one of the most common diseases in the in-
dustrial world [30]. AD is clinically characterised by a
slow but progressive loss of memory and cognitive func-
tions that leads to dementia [32] and ultimately to death
[33]. Pathological hallmarks of the disease are the extra-
cellular senile plaques composed of aggregated and misfol-
Review article: Medical intelligence Swiss Med Wkly. 2015;145:w14192
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 22
ded β-amyloid (Aβ) peptide and intracellular neurofibril-
lary tangles made of hyperphosphorylated tau protein, ac-
companied by microvascular damage and neuroinflamma-
tion [33]. Vast and broad loss of brain weight and volume
is most likely caused by shrinkage and subsequent loss
of neuronal processes, as well as specific loss of neurons
within the entorhinal cortex and the hippocampus [34]. The
majority of AD cases (>95%) do not show clear inherit-
ance and they are called sporadic or late-onset AD. Never-
theless, several genetic factors were shown to contribute to
the development of sporadic AD [33]. On the other hand,
mutations in the amyloid precursor protein (APP), presenil-
in 1 (PSEN1) and presenilin 2 (PSEN2) all lead to aggrega-
tion of the Aβ peptide and cause the early-onset, autosomal
dominant form of AD [30] with Mendelian inheritance.
miRNA-mediated regulation of the amyloid precursor
protein
Numerous studies of miRNAs in AD have been performed
both in AD models and human AD patient samples. It is
clear that miRNAs are deregulated in AD [35] and that
miRNA levels change according to disease stage [36, 37]
or AD type [38]. Direct APP mRNA regulation and sub-
sequent decrease of Aβ accumulation has been shown for
miR-101 in vitro [39, 40] and for miR-384 both in vitro and
in cerebrospinal fluid (CSF) and serum of AD patients [38].
In addition, miR-384 also targets and regulates BACE1 (β-
secretase 1; β-site APP cleaving enzyme 1), which in turn
also indirectly represses the Aβ load, as a negative correla-
tion between miR-384 and Aβ42 was observed in serum and
CSF of AD patients [38]. Several other miRNAs (miR-20a,
miR-17, miR-147, miR-655, miR-323-3p, miR-644,
Table 1: Reported miRNA alternations in neurodegenerative diseases.
Dysregulation in patient samplesDisease
Up in CNS Down in CNS Up in periphery Down in periphery
Alzheimer’s
disease
miR-26b (temporal cortex)[56]
miR-9, miR-128 (CA1
hippocampus)[58]
miR-124 (anterior temporal
cortex)[42]
miR-107 (superior and middle
temporal cortex)[37]
miR-29a, miR-29b-1 (high BACE1
brain)[50]
miR-29a (cerebral cortex)[53]
miR-132-3p (prefrontal cortex)[57]
miR-146b (hippocampus, frontal
gyrus)[36]
miR-9, miR-125b, miR-146a,
miR-155 (CSF, neocortex ECF) [43]
miR-34a, miR-181b, let-7f,
miR-200a (blood mononuclear
cells)[54]
let-7d-5p, let-7g-5p, miR-15b-5p,
miR-142-3p, miR-191-5p,
miR-301a-3p and miR-545-3p
(plasma)[59]
miR-384 (blood, CSF)[38]
Parkinson’s
disease
miR-133b (midbrain)[69]
miR-205 (frontal cortex,
striatum)[73]
miR16-2*, miR26a2* (peripheral
blood early onset patients)[78]
miR-331-5p (plasma)[79]
miR1, miR-22*, miR-29a (peripheral
blood non-treated patients)[78]
miR-126* (peripheral blood
mononuclear cells)[237]
Amyotrophic
lateral sclerosis
miR-624, miR-520e, miR-524-5p,
miR-548a-5p, miR-606, miR-612,
miR-647 (sporadic ventral lumbar
spinal cord)[136]
miR-b1123, miR-b2948, miR-b3265,
miR-b5539, miR-sb1217*, miR-
sb3998 (novel miRNA with MREs in
NEFL mRNA 3′UTR, sporadic
ventral lumbar spinal cord)[137]
miR-24-2*, miR-142-3p,
miR-142-5p, miR-146a, miR-146b,
miR-155 (spinal cord)[163]
miR-9, miR-9-2 (human iPSC-
derived neurons)[134]
239 different miRNAs (sporadic
ventral lumbar spinal cord)[136]
miR-b1336, miR-b2403, miR-b4652,
miR-sb659* (novel miRNA with
MREs in NEFL mRNA 3′UTR,
sporadic ventral lumbar spinal
cord)[137]
miR-23a, miR-29b, miR-206,
miR-455 (skeletal muscle)[151]
miR106b, miR-206 (serum)[152]
miR-338-3p (sporadic peripheral
blood leucocytes)[167]
miR-143-5p, miR-574-5p (sporadic
CSF)[168]
miR-451, miR-1275, miR-328-5P,
miR-638, miR-149, miR-655
(sporadic peripheral blood
leucocytes)[167]
miR-132-5p, miR-132-3p,
miR-143-3p (sporadic CSF)[168]
miR-132-5p, miR-132-3p,
miR-143-5p, miR-143-3p, let-7b
(sporadic serum)[168]
miR-574-3p, miR-574-5p (TARDBP,
FUS, C9ORF72 and sporadic
mutant Epstein-Barr virus
transformed lymphoblastoid cell
lines)[168]
miR-663a, miR-9-5p (FUS mutant
LCLs)[168]
Let-7b (FUS and C9ORF72 mutant
LCLs)[168]
Huntington’s
disease
miR-29a, miR-330 (cortex, Brodman
area 4)[181]
miR-132 (cortex, Brodman area
4)[135]
miR-196a[185], miR-486 (cortex,
Brodman area 4, only HD1
grade)[135]
miR-100, miR-151-3p, miR-16,
miR-219-2-3p, miR-219-5p,
miR-27b, miR-451, miR-92a (frontal
cortex, striatum)[16]
miR-10b-5p, miR-1247-5p,
miR-196a-5p, miR-196b-5p, and
miR-615-3p (prefrontal cortex
Brodmann area 9)[189]
miR-132 (cortex, Brodman area
4)[181]
miR-9, miR-9*, miR-29b, miR-124a
(cortex, Brodman area 4)[135]
miR-128a (human pre- and post-
symptomatic brain)[184]
miR-128, miR139-3p, miR-222,
miR-382, miR-433, miR-485-3p
(frontal cortex, striatum)[16]
miR-34b (plasma, pre-manifest
HD)[166]
3’UTR = 3’untranslated region; BACE-1 = β-secretase; CNS = central nervous system; CSF = cerebrospinal fluid; ECF = extracellular fluid; HD = Huntington’s disease;
iPSC = induced pluripotent stem cell; MREs = molecular recognition elements; mRNA = messenger RNA; NEFL = neurofilament light subunit;
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miR-153) were shown to regulate APP expression in vitro
and in cells [41]. Moreover, as shown in cultured cells,
some AD-linked mutations in APP interfere with miRNA
binding, such as the T117C APP variant, which inhibited
miR-147 binding, and the A454G APP variant, which in-
creased miR-20a binding [41]. Alternative splicing of APP
is also regulated by miR-124, which is reduced in AD
brains leading to APP missplicing [42]. Upregulation of
nuclear factor kappa-light-chain-enhancer (NF-κB)-sensit-
ive inflammatory miRNAs (miR-9, miR-125b, miR-146a,
miR-155) was reported in the CSF and extracellular fluid
(ECF) from AD neocortex, where Aβ42 levels were slightly
reduced, compared with other brain regions, suggesting a
role for these miRNAs in the pathogenic signalling of AD
[43], potentially disturbing the fine tuning of inflammat-
ory responses as it has been shown that dysregulating only
miR-155 or miR-146 is sufficient to trigger autoimmune
disease [44–47].
miRNA-mediated regulation of β-secretase 1
Beta-secretase 1 (BACE1) is the proteolytic enzyme that
cleaves APP at the β-site APP, resulting in the production
of Aβ. BACE1-targeting miRNAs therefore regulate APP
Figure 1
miRNA alternations in neurodegenerative diseases. Numerous
alternations in miRNA biogenesis and function were found to
contribute to the pathogenesis of several neurodegenerative
diseases including: (A) In HD, miRNA transcription is disturbed as
mutant huntingtin does not bind REST (which is normally bound to
wild-type huntingtin), allowing the formation of NRSE thus
repressing the transcription of neuronal miRNAs [135, 181, 183].
Mutant huntingtin also binds to p53 dysregulating p53-mediated
transcription of miRNAs [16, 188]. (B) Downregulation of miR-124
has been found to cause missplicing of APP in AD [42]. (C) Ago
has been found to be sequestered by mutant huntingtin and
accumulated into stress granules in HD suggesting impaired
miRNA-mediated mRNA regulation [189–191]. Interestingly, mutant
LRRK2 also interacts with Ago, impairing mRNA regulation by
miRNAs [72]. (D) Expression of APP and BACE1 in AD [37–41,
48–52] and SNCS and LRRK2 in PD [71-73] has been described to
be specifically affected by their regulating miRNA(s) that are
disturbed in these diseases. (E) Non-cell autonomous
neurodegeneration is now well recognized in ALS and miR-155
seems to play a major role in the pathologic microgliosis [43, 163,
165].
3’UTR = 3’ untranslated region; AD = Alzheimer’s disease; ALS =
amyotrophic lateral sclerosis; APP = amyloid precursor protein;
BACE-1 = β-secretase 1; HD = Huntington’s disease; HTT =
huntingtin gene; LRRK2= leucine-rich repeat kinase 2; miRNA =
microRNA; mRNA = messenger RNA; NRSE = neuron restrictive
silencer element; PD = Parkinson’s disease; pri-miRNA = primary
miRNA; REST = RE1-silencing transcription factor; RISC = RNA-
induced silencing complex
and Aβ indirectly. The miR-107 targets BACE1 mRNA
and since miR-107 levels significantly decrease during AD
progression, BACE1 mRNA levels subsequently increase
[37]. Also, miR-195 was shown to regulate negatively
BACE1 and Aβ in cell lines and in the SAMP8
(senescence-accelerated) mouse model, which developes
AD signs [48]. Both miR-298 and miR-328 have been
shown to regulate BACE1, as their overexpression in cell
lines and primary neurons showed lower BACE1 levels
[49]. BACE1 expression can be regulated by miR-29a,
miR-29b-1, and miR-9 in cultured cells, and the miR-29a/
b-1 cluster was significantly decreased in AD brain dis-
playing abnormally high BACE1 protein [50]. Results from
cultured cells also showed that miR-124 directly regulates
BACE1 expression, with miR-124 downregulation leading
to increased BACE1 levels and Aβ neurotoxicity [51].
Overexpression of miR-29c in cell lines and transgenic
mice (APPswe/PSΔE9) leads to reduced levels of BACE1
[52]. Interestingly, miR-29a is significantly downregulated
in human AD brains, leading to the upregulation of its tar-
get, neuron navigator 3 (NAV3), in degenerating pyramidal
neurons in the cerebral cortex [53].
Misregulation of miRNAs in Alzheimer’s disease
In a miRNA microarray screen followed by quantitive
polymerase chain reaction (qPCR) validation of hits,
Schipper and colleagues demonstrated that miR-34a and
miR-181b are significantly upregulated in blood mononuc-
lear cells of patients with sporadic AD, while their ex-
pression differed between AD subjects bearing one or two
APOE4 alleles [54]. Also, miR-34a was shown to har-
bour a 3’-untranslated region (3’UTR) binding site on tau
mRNA, thereby directly repressing tau expression in cul-
tured cells [55]. Misregulation of miRNAs occurs already
in the early stages of AD (Braak III), such as elevation
of miR-26b, which leads to apoptosis in primary neurons
[56] and decrease of miR-132-3p [57] in postmortem AD
brains. Importantly, the latter appears to occur mostly in
neurons with tau hyperphosphorylation [57]. In addition to
the above, numerous miRNAs were found to be deregu-
lated across different brain areas and AD stages, both in
brain and CSF. All members of the miR-30 family were
upregulated in CSF while only miR-146b was consistently
altered in both hippocampus and medial frontal gyrus in
early and late stages of the disease [36]. Moreover, miR-9,
miR-125b, miR-146a and miR-155 were upregulated in
CSF and ECF of AD patients [43], while miR-384 was
downregulated in both serum and CSF of AD patients [38].
Further, miR-9 was found to be upregulated in AD CSF
and ECF [43] and hippocampus [58], but downregulated
in neocortex [50], also suggesting differential spatial reg-
ulation of miRNAs in AD brain. The miRNA signature
is also altered in the blood of AD patients. Indeed, blood
mononuclear cells of AD subjects showed significantly in-
creased levels of miR-34a and miR-181b [54]. Finally, us-
ing nCounter miRNA expression assay v1 (high-through-
put expression profiling of miRNAs using digital detection
and counting of miRNAs in a single reaction without amp-
lification) followed by qPCR validation, let-7d-5p,
let-7g-5p, miR-15b-5p, miR-142-3p, miR-191-5p,
miR-301a-3p and miR-545-3p were all shown to be signi-
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ficantly upregulated in plasma of AD patients, providing
differentiation of AD patients from normal controls with
>95% accuracy [59].
Taken together, the above results clearly demonstrate the
high potential of miRNAs as biomarkers for AD. Discrep-
ancies between studies, however, indicate that additional
multicentre in-depth studies are necessary to identify and/
or confirm miRNAs that could represent reliable biomark-
ers for AD.
Parkinson’s disease
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder, which affects an estimated 1%
of individuals over 60 years of age, a percentage that is ex-
pected to double by 2030 as the population ages [60]. PD
is a progressive neurodegenerative disease presenting with
resting tremor, bradykinesia, rigidity, postural instability
and dementia [61]. These symptoms are attributed to loss
of dopamine neurons in the substantia nigra pars compacta,
as well as widespread neuropathological changes in mul-
tiple brain regions, including the amygdala, cingulate gyrus
and cerebral cortex [61]. The pathological hallmark of PD
are Lewy bodies, intraneuronal inclusions that mainly con-
tain aggregated α-synuclein, often in association with neur-
ofilaments and ubiquitin [62]. It has been shown that ex-
pression of mutant as well as overexpression of wild-type
α-synuclein leads to development of PD [63]. PD is mainly
sporadic and is believed to develop as a consequence of
multiple genetic and possibly environmental factors in an
aging brain. Mutations in approximately 15 genes were re-
ported to cause rare cases of familial PD, including muta-
tions in α-synuclein, LRRK2, parkin, PINK1, DJ-1 [64].
Interestingly, it is well-recognised that temporary Parkinso-
nian symptoms represent a common side effect of several
drugs that usually vanishes after drug withdrawal [65].
However, specific cases of irreversible Parkinsonism were
described in the late 70s and early 80s among drug abusers
in the USA. The chemical compound responsible for the
PD-like symptoms and severe neuronal loss in the sub-
stantia nigra was later identified to be MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), the side
product in synthesis of the ‘new synthetic heroin’, MPPP
(1-methyl-4-phenyl-4-propionoxypiperidine) [65–67].
Subsequently, MPTP became one of the most commonly
used neurotoxins to model PD in experimental animals
[68].
miRNAs were first suggested to be involved in PD patho-
logy by deletion of Dicer specifically in mouse dopaminer-
gic neurons, which resulted in their loss and consequently
in reduced locomotion [69]. Levels of miR-133b are signi-
ficantly decreased in the midbrain of PD patients compared
with controls, leading to increased levels of the transcrip-
tion factor Pitx3, which in turn specifically induces tran-
scription of miR-133b in a negative feedback loop that is
important for neurogenesis and function of dopaminergic
neurons [69]. Later studies revealed that miRNAs are dir-
ectly involved in PD pathogenesis, regulating pathways of
PD-linked genes and their protein products. Through use
of cultured cells, brain enriched miR-7 [70] and miR-153
[71] have been shown to inhibit SNCA mRNA and conse-
quently α-synuclein protein targeting the 3’UTR of SNCA,
suggesting that upregulation of miR-7 and miR-153 may
represent a viable therapy for PD [71]. Mutant leucine-rich
repeat kinase-2 (LRRK2) inhibits let-7 and miR-184* func-
tion leading to upregulation of their targets, E2F1 and DP,
respectively, ultimately causing LRRK2-linked dopaminer-
gic neuron pathogenesis in Drosophila [72]. Importantly,
mutant LRRK2 has been shown to interact with and reg-
ulate argonaute protein in both Drosophila brains and cul-
tured cells [72], suggesting global miRNA deregulation.
Moreover, miR-205 has recently been shown to be down-
regulated in the brains of sporadic PD patients, with in-
creased LRRK2 levels [73]. Since miR-205 directly reg-
ulates LRRK2 mRNA and protein, downregulation of
miR-205 may contribute to pathogenic elevation of
LRRK2 and, therefore, overexpression of miR-205 may
represent potential therapy for PD [73]. SNPs in the 3’UTR
of FGF20 were shown to be regulated by miR-433 in both
cultured cells and in PD brains [74] and are associated with
elevated levels of both FGF20 and α-synuclein, which has
been linked to increased risk of developing PD [74, 75], but
the association between FGF20 and PD remains controver-
sial [76, 77].
Circulating miRNAs in peripheral blood were shown to
differentiate control individuals from untreated PD patients
(miR-1, miR-22, miR-29) and untreated from treated PD
patients (miR-16-2, miR-26a2, miR30a) [78]. However, a
later study with a substantially larger cohort of plasma
samples did not confirm those results and instead showed
only miR-331-5p to be significantly upregulated in PD pa-
tients [79]. Clearly, differences in sample types and pa-
tient cohorts are most likely the reason for these variations
and more comprehensive studies are needed to identify the
right miRNAs that are present across different PD types.
Nevertheless, these results are encouraging and represent a
huge step towards easily accessible and reliable biomarkers
of PD.
Prion diseases
Prion diseases, also known as transmissible spongiform en-
cephalopathies, are a group of rare fatal neurodegenerative
disorders marked by neuronal loss, gliosis and spongiform
changes in the brain. Prion diseases include Creutzfeldt-
Figure 2
Proposed new strategies for high throughput small RNA screens to
discover cell signalling mechanisms and novel therapeutic target for
prion disease.
HTS = high throughput screening; sgRNA = single guide RNA;
shRNA = short hairpin RNA; siRNA = small interfering RNA
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Jakob disease in humans, scrapie in sheeps and goats,
chronic wasting disease in deer and elk, and the bovine
spongiform encephalopathy in cattle [80]. The disease-
causing agent consists of PrPSc, which is an isoform of the
host-encoded cellular prion protein PrPC. PrPSc acts as a
propagon that is capable of seeding a self-perpetuating re-
action to convert PrPC to the pathological conformation of
PrPSc within a bioassay system [80], a process termed prion
replication.
The expression of PrPC is indispensable for prion replic-
ation and prion-induced neurodegeneration. However, the
intrinsic mechanisms underlying prion replication and sub-
sequent neurodegeneration are largely unknown [81].
Several key questions, including the genes and proteins
that regulate endogenous PrPC expression, the machinery
of PrPC to PrPSc conversion, and the molecules affecting
susceptibility to prion infection and cell-to-cell spread of
prions, have not been answered yet. This is mainly because
of the dearth of high-throughput technologies that can be
used to identify these mechanisms, which would not only
greatly improve our basic understanding of prion patho-
physiology, but might also uncover novel therapeutic and
diagnostic targets. Here we discuss the application of small
RNA-based technologies in prion studies.
RNA profile change in neuronal cells upon prion
infection
Upon prion infection of neuronal cell lines, the transcrip-
tome profile changes reflect the direct response to prions
and could indicate potential pathways leading to prion
pathogenesis. Greenwood et al. performed the first study
using a complementary DNA (cDNA) microarray and ob-
served strikingly different expression profiles in both
ScN2a and ScGT1 cells upon persistent prion infection
[82]. Interestingly, many of the differentially regulated
genes were also observed to change in other neurodegen-
erative disorders, suggesting some conserved responses to
neurological damage in various neurodegenerative condi-
tions. However, another transcriptional study conducted by
Julius et al. analysed the transcriptome of several prion-
infected cell lines (N2aPK1, CAD and GT1) under more
stringently controlled conditions. By applying high-density
oligonucleotide microarray analysis and exhaustive bioin-
fomatical interrogation of the data, Julius et al. identified
very modest differential expression resulting from prion in-
fection [83]. The discrepancy between the two studies may
be due to differences in experimental design, cell culture
conditions and/or prion infection processes. Among many
possible factors, the clonal segregation strategy used in the
Greenwood study might have resulted in differential tran-
scriptional responses independent of prion infection.
The transcriptional profile of cell culture might change
after prion infection; likewise, the transcriptome of cell
lines could also affect the susceptibility to prion infection.
Different cell lines have distinct susceptibilities to prion
infection. These differences cannot be explained only by
the PrPC expression levels, which are required but not suf-
ficient for prion replication [84]. Recently, Marbiah et al.
isolated prion-resistant revertants from susceptible cells.
By comparing the transcriptome of prion-resistant rever-
tants to that of susceptible cells, Marbiah et al. revealed a
gene regulatory network for extracellular matrix remodel-
ling that is associated with prion propagation.
The roles of miRNAs in prion diseases remain unclear.
By using microarray and real-time PCR (RT-PCR), Saba
et al. profiled miRNA expression changes in the brains of
mice intracerebrally inoculated with mouse scrapie. Fif-
teen miRNAs were found to be deregulated during the
disease processes and only one of them had previously
been shown to be deregulated in neurodegenerative disease
[85], suggesting a prion disease-specific pattern of dif-
ferentially expressed miRNAs. In addition, a correlation
between miRNA expression profile and expression change
on putative gene targets was identified. Further studies are
required to determine the cell types in which miRNAs are
deregulated.
In conclusion, with proper experimental strategies and ap-
plication of new RNA analysis technologies such as RNA
sequencing, we expect that our understanding of the cel-
lular transcriptional response to prion infection will be
deepened. The identification of RNA profile changes upon
prion infection may have potential use as biomarkers for
prion diagnostics and therapeutic targets.
Small RNA-based target-identification and potential
therapeutics for prion disease
PrPC is indispensable for prion replication and prion-in-
duced pathogenesis. Mice devoid of PrPC showed resist-
ance to prion infection [86]. PrPC reduction of 50%
(Prnp+/– heterozygous mice) significantly prolongs the in-
cubation time of prion disease in mouse, while overex-
pression of PrPC markedly shortens prion disease progres-
sion [87]. Therefore, identification of genes involved in
PrPC biosynthesis by use of small RNA-based screening
and RNA-mediated modulation of PrPC expression accord-
ingly have great potential to mitigate the PrPC-PrPSc con-
version, diminish prion-induced neurotoxicity and conse-
quently slow disease progression.
Since Prnp is the main determinant for prion pathogenesis,
small RNAs specifically and directly targeting Prnp have
been extensively studied for prion therapeutics both in vitro
and in vivo. Small interfereing RNA duplexes targeting
the Prnp gene effectively suppressed expression of PrPC
in prion-infected N2a cells and inhibited PrPSc accumula-
tion [88]. A liposome-siRNA-peptide complex was later
developed to suppress PrPC expression and eliminate PrPSc
formation in prion-infected N2a cells [89]. Additionally,
the vector-based short hairpin RNA (shRNA) was success-
fully applied to decrease PrPC expression in rabbit kidney
epithelial cells [90] and mouse N2a cells [91]. Lentiviral
vector delivered shRNA also decreased PrPC levels and ex-
tended the prion incubation time in mice [91, 92]. Simil-
ar effects were observed in transgenic livestock [93, 94],
Therefore, RNA interference (RNAi) based Prnp knock-
down represents a promising approach for prion therapeut-
ics. However, there are concerns about RNAi-based thera-
peutics, such as immunogenicity and off-target induced
cytotoxicity. Hence, modified versions of small RNAs or
novel small RNAs targeting Prnp may circumvent those
pitfalls. Recently, miRNA [95], DNA-based antisense oli-
gonucleotides [96], and RNA aptamers [97, 98] targeting
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Prnp/PrPC have been shown to prevent prion disease pro-
gression.
HTS assays including PrP-FEHTA (PrP-FRET-enabled
high throughput assay) [99] and ELISA (enzyme-linked
immunosorbent assay) [100] have been applied to search
for small compounds that may reduce PrPC expression for
prion therapy, albeit no strong candidates have been dis-
covered yet. An alternative strategy is RNAi screening,
which is based on RNA-mediated gene silencing that can
reduce levels of the mRNA target [101]. RNAi HTS has
become a powerful tool for whole transcriptome manip-
ulation and thus discovery of signalling mechanisms and
therapeutic strategies in human diseases [101]. Transcrip-
tome wide RNAi screenings (siRNA or shRNA libraries)
are likely to uncover genes and proteins that are involved in
PrPC biosynthesis. Moreover, the advent of CRISPR-Cas9
mediated single guide RNA (sgRNA) library HTS provides
another alternative approach to interrogation of the mo-
lecular networks that regulate PrPC biosynthesis. Hits iden-
tified by those RNA-based HTS represent potential targets
for modulating PrPC expression and therefore therapeutics
for prion disease.
In addition, RNA-based HTS can be applied to identify
genes and proteins that are involved in prion replication.
However, this application is challenging because the con-
ventional quantification of prion infectivity is performed
by titration of serial dilutions using mouse bioassays [102]
or standard scrapie cell endpoint assays [103]. Both ap-
proaches are either protracted or demanding substantial
manual work, hence are not applicable for HTS. Therefore,
new methodologies and technologies are required to meet
the need of a reliable prion infectivity assay complement-
ary to an automated high-throughput system, which will
facilitate HTS of entire small RNA libraries including
siRNA, shRNA or the newly developed sgRNA libraries,
as well as compounds and peptides, with the aim of identi-
fying disease relevant genes, early molecular markers and
novel therapeutics (fig. 2). The progress of small RNA-
based HTS technology is exciting and may contribute to
the discovery of promising therapeutic targets for prion dis-
eases and other neurodegenerative diseases.
Amyotrophic lateral sclerosis and
frontotemporal dementia
Amyotrophic lateral sclerosis (ALS; also known as Lou
Gehrig’s disease [USA] and motor neuron disease [UK]) is
a late onset, progressive and fatal neurodegenerative dis-
ease characterised by loss of upper motor neurons in the
motor cortex and lower motor neurons in the brain stem
and spinal cord. Motor neuron neurodegeneration in ALS
leads to muscle atrophy, weakness, fasciculation and spas-
ticity, followed by paralysis and ultimately death, typically
due to respiratory failure [104]. First described in 1869 by
Jean-Martin Charcot (therefore initially known as a Char-
cot’s disease), ALS was named based on his observations
of distinct loss of axons in the lateral aspect of the spinal
cord [105]. Typical onset of the disease is usually in mid-
life (45-60 years) with an uncompromisingly progressive
disease course of 3 to 5 years [106]. Worldwide inciden-
ce and prevalence of ALS are 1–2 and 4–6 per 100 000
each year, respectively, with a lifetime ALS risk of 1/350
to 1/1 000 [107, 108] and incidence peak (10–15/100 000/
year) between ages 60 and 79 [109]. The vast majority
of ALS cases (~90%) are sporadic with no family history.
Sporadic ALS includes patients carrying de novo muta-
tions or alleles with incomplete penetrance, or with an in-
complete family history. The remaining 10% of ALS cases
are caused by autosomal dominant mutations and therefore
called familial ALS. Approximately 20% of familial ALS
cases are associated with mutations in a gene coding for
an antioxidative enzyme, the copper/zinc superoxide dis-
mutase 1 (SOD1) [110]. Recent identification of causative
mutations in the 43-kDa transactive response (TAR) DNA-
binding protein (TDP-43) [111–5] and fused in sarcoma/
translocated in sarcoma (FUS/TLS) [116, 117], which are
both involved in RNA processing, in conjunction with the
recognition that TDP-43 is the main protein component of
the ubiquitinated inclusions in the vast majority of ALS pa-
tients [118, 119], led to the idea that aberrant RNA meta-
bolism contributes to ALS pathogenesis [106, 120, 121].
More recently, hexanucleotide expansions in an intronic re-
gion of a poorly characterised gene called C9ORF72 (chro-
mosome 9 open reading frame 72) were identified as the
most common genetic cause of ALS [122–4]. This finding
corroborated the link between ALS and frontotemporal de-
mentia (FTD), which are now recognised as two clinical
ends of one disease spectrum [106, 125, 126]. Indeed, it is
estimated that about 20% of ALS patients develop signs of
frontotemporal dementia [127] and that about 15% of FTD
patients develop motor neuron degeneration [126, 127].
FTD is the clinical presentation of frontotemporal lobar de-
generation (FTLD), which is a neurodegenerative disease
characterised by progressive neuronal loss, predominantly
involving the frontal and temporal lobes [128], that primar-
ily affects behaviour, social awareness and language [129].
FTD has only recently been appreciated as one of the lead-
ing causes of dementia, particularly in patients younger
than 65 years [130], making it the second most common
cause of early onset dementia after Alzheimer's disease
[131]. Data from the UK show a prevalence of around 15
cases per 100 000 population aged 45–64 years [131]. Ap-
proximately 50% of all FTD cases are familial with the
microtubule-associated protein tau (MAPT) and progran-
ulin (PGRN) accounting for 10%–20% of FTD cases [126].
Rare cases of FTD are caused by mutations in TDP-43 and
FUS/TLS [120] but the strongest genetic link between ALS
and FTD is the hexanucleotide expansion in C9ORF72
which is the most common genetic cause of FTD-ALS
and accounts for a large number of FTD cases (10%–30%)
[122–4, 126].
miRNA miR-9 in (motor) neurons
miRNA is essential for normal function of spinal motor
neurons as ablation of Dicer1 in motor neurons induced
denervation, muscle atrophy, astrogliosis and motor neur-
onal loss [132]. Deletion of Dicer in astrocytes led to sig-
nificant downregulation of astrocyte-specific glutamate
transporters GLT-1 and GLAST resulting in non-cell
autonomous neuronal dysfunction and degeneration,
demonstrating its crucial role in these glial cells [133]. In-
terestingly, in a mouse model of a loss of miRNA function
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in spinal motor neurons (MNDicerMUT mice), miRNA-de-
ficient spinal motor neurons showed specific upregulation
of the neurofilament heavy subunit (NEFH) that has been
previously linked to motor neuron degeneration. Coordin-
ated neurofilament gene expression is necessary for normal
neuronal function and upregulation of only NEFH in the
motor neurons of MNDicerMUT mice, suggests possible
perturbation in the fine-tuning of related genes by
miRNAs. Indeed, authors found a single miR-9–binding
site on the neurofilament light subunit (NEFL) mRNA and
nine different sites in the NEFH mRNA. Furthermore, mo-
tor neurons differentiated from mouse embryonic stem
cells harbouring an SMN1 mutation revealed a 15-fold de-
crease in the expression of both miR-9 and miR-9* [132].
Importantly, human ALS neurons derived from induced
pluripotent stem cells (iPSCs) (TARDBP A90V mutation)
also displayed downregulation of miR-9 and miR-9-2
[134], which may be a common mechanism in several
neurodegenerative diseases, including ALS, FTD, spinal
muscular atrophy and Huntington’s disease. Indeed, miR-9
and miR-9* have been shown to regulate directly
RE1-silencing transcription factor (REST) and CoREST,
respectively, which could lead to increased or mislocalised
pools of REST thereby dysregulating neuronal genes [135].
In addition, miR-9, among others, was also found to be
significantly downregulated in the spinal cord of human
sporadic ALS patients [136]. However, this study describes
NEFL mRNA suppression by dysregulated miR-146a*,
miR-524-5p and miR-582-3p, which are capable of direct
binding to NEFL mRNA [136]. Moreover, the same group
reported that additional miRNAs that normally stabilise
NEFL mRNA, miR-b1336 and miR-b2403, were downreg-
ulated in ALS spinal cord, thereby contributing to the loss
of NEFL steady-state levels [137]. In contrast to the find-
ings in human ALS samples, miR-9 expression was upreg-
ulated in the spinal cord of SOD1G93A mice at early and
late symptomatic stages [138], suggesting that this mech-
anism may vary among different types of ALS with dis-
tinct pathologies (primarily TDP-43 pathology in sporadic
ALS or TARDBP A90V mutation carriers, versus misfol-
ded SOD1 in the SOD1G93A mice).
TDP-43 and FUS miRNA regulation
The physiological role of the ALS/FTD-linked RNA-bind-
ing proteins TDP-43 and FUS has been extensively studied,
which showed that they are involved in many aspects of
RNA metabolism (reviewed in [120, 121, 126]), including
miRNA regulation. Indeed, TDP-43 was shown to associ-
ate with Drosha [139] and Dicer complexes [140, 141], an
interaction that may be disturbed by ALS-linked mutations
that increase the protein half-life of TDP-43 [139], thereby
interfering with miRNA biogenesis. In addition, FUS in-
teraction is required for efficient recruitment of Drosha at
specific pri-miRNA sites at early stages of transcription
thereby stimulating miRNA biogenesis [149].
TDP-43 knockout in cultured cells led to downregulation
of let-7b and upregulation of miR-663 expression [142].
Fan and colleagues recently applied transcriptome-wide
analysis of TDP-43 binding small RNAs on previously
published CLIP-seq data from human and mouse samples
[144, 145]. Their analysis identified a novel NRXN1
intron-derived miRNA, called miR-NID1, found in both
human and mouse [143]. This miRNA is located in the fifth
intron of human neurexin 1 (NRXN1) and four pre-miR-
NID1 candidates are located in the introns of protein cod-
ing genes in the mouse. Functional analysis by means of
nucleocytoplasmic fractionation and RNA immunoprecip-
itation assays in SY-5YC cells revealed that endogenous
TDP-43 is associated with miR-NID1 in both cytoplasm
and nuclei and that miR-NID1 represses the expression of
NRXN1 through TDP-43 [143].
Overexpression of human wild type FUS in transgenic
mouse models has been shown to induce progressive motor
neuron degeneration [146] and its deficiency resulted in
chromosomal instability and perinatal death [147]. FUS
carrying a 3’UTR G48A mutation, which affects the bind-
ing site of miR-141/200a, renders FUS mRNA insensitive
to repression by these miRNAs [148]. Furthermore, as
shown in SK-N-BE neuroblastoma cells, FUS controls
miR-141/200a biogenesis suggesting a feed-forward regu-
latory loop in which FUS increases the expression levels
of two miRNAs, which in turn regulate FUS accumulation
and an increase in nuclear FUS protein [148]. Moreover,
expression of a subset of miRNAs known to have a crucial
role in neuronal function, differentiation and synaptogen-
esis (miR-9, miR-125b and miR-132), is altered upon FUS
knockdown in cultured cells [149].
Espression of miR-206 in ALS
The importance of miR-206 expression in ALS was first
highlighted by a study on neuromuscular junctions of
mutant SOD1 mice [150]. The investigators found that
skeletal muscle-specific miR-206 is dramatically increased
in the SOD1G93A mouse model of ALS. In this study, they
generated miR-206 knockout mice, which were also
crossed with transgenic mice expressing low levels of
SOD1G93A. The miR-206 knockout mice developed nor-
mally but the SOD1G93A mice lacking miR-206 displayed
exacerbation of disease symptoms accompanied by accel-
erated atrophy of skeletal muscle, leading to kyphosis,
paralysis and death [150]. It has been shown that axonal
branches of surviving motor neurons are partially rein-
nervating muscles whose innervating motor neurons have
already died during the course of ALS. Also, miR-206
slows ALS progression by sensing motor neuron injury and
promoting the compensatory regeneration of neuromus-
cular synapses via induced secretion of fibroblast growth
factor binding protein 1 (FGFBP1) from muscle by inhibit-
ing HDAC4 translation [150]. This has been confirmed in
patients as miR-23a, miR-29b, miR-206 and miR-455 were
all increased in skeletal muscle of ALS patients compared
with healthy controls [151]. It was found that miR-23a
repressed PGC-1α translation in a 3′UTR dependent man-
ner in vitro and that transgenic mice overexpressing
miR-23a had a reduction in PGC-1α, cytochrome-b and
COXIV protein levels leading to skeletal muscle mitochon-
drial dysfunction in ALS [151]. Recently, miR-206 was
found to be consistently increased in fast-twitch muscles
during the course of the disease in SOD1G93A mice, with
highest expression levels towards the end stage [152]. Most
importantly, miR-206 was also found to be significantly el-
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evated in circulating blood of both SOD1G93A mice and hu-
man ALS patients [152].
Dysregulation of miRNAs in frontotemporal dementia
FTD and ALS are linked clinically, pathologically and mo-
lecularly by several lines of evidence and thus represent
two ends of a disease spectrum [153]; therefore, a common
miRNA biogenesis dysregulation by mutant TDP-43 and
FUS can be expected. Nevertheless, progranulin (GRN)
mutations are exclusively found to cause FTD and loss of
progranulin function causes tau negative FTD with TDP-43
and ubiquitin pathology (FTD-TDP) [154, 155]. Moreover,
a common genetic variant (rs5848), located in the 3’UTR
of GRN within a binding-site for miR-659, is a major sus-
ceptibility factor for this type of FTD, as miR-659 binds
the high-risk T allele of rs5848 more efficiently, resulting
in enhanced translational inhibition of GRN [156]. Using
miRNA array profiling and qPCR validation in both frontal
cortex and cerebellum of FTD-TDP patients carrying GRN
mutations, the same group found that miR-922,
miR-516a-3p, miR-571, miR-548b-5p, and miR-548c-5p
are exclusively dysregulated in these patients when com-
pared with FTD-TDP patients without GRN mutations
[157]. A genome-wide association study showed that chro-
mosome 7p21 variants within the gene TMEM106B confer
increased risk of developing FTD-TDP [158]. The same
group later found that TMEM106B is repressed by miR-132
and miR-212 and that both miRNAs are downregulated
in FTD-TDP leading to aberrant overexpression of
TMEM106B that affects the distribution and intracellular
levels of progranulin, suggesting that the two proteins may
act in the same pathogenic pathway in FTD-TDP [159].
Specific SNPs in the TMEM106B gene seem to regulate
progranulin levels and thereby the penetrance of FTD in
GRN mutation carriers [160]. Recently, TMEM106B has
been identified as the first genetic factor modifying disease
presentation in C9ORF72 expansion carriers, as homozy-
gosity for the minor rs3173615 allele protects carriers from
developing FTD, but not from developing ALS [161]. Fur-
thermore, a SNP that confers increased risk for developing
FTD-TDP (major, or T, allele of rs1990622) and which is
associated with later age at onset and death in C9ORF72
expansion carriers has been also identified [162]. Most re-
cently, a genotype that confers decreased risk for develop-
ing FTD-TDP (minor, or C, allele of rs1990622) has been
found to be associated with earlier age at onset and death in
C9ORF72 expansion carriers [134] completing the picture
of TMEM106B as a genetic modifier in ALS and FTD.
miRNA overexpression or inhibition as a potential
therapy in ALS/FTD
The levels of miR-206 are significantly elevated in muscles
[150] and plasma [152] of SOD1G93A mice, and in the
plasma of sporadic ALS patients [152]. Since miR-206
senses damage in motor neurons and promotes compens-
atory mechanisms that lead to regeneration of neuromus-
cular junctions, its increased expression acts to counteract
disease progression in the SOD1G93A mouse model, but ul-
timately fails to completely reverse disease [150]. Never-
theless, it is possible that overexpression of miR-206 in
skeletal muscles could further delay the muscle weakness
observed in ALS patients, thereby providing a potential
palliation approach.
Recent microarray screens revealed that miR-155 is signi-
ficantly upregulated in SOD1G93A mouse and human ALS
patient spinal cords [163], as well as in peripheral mono-
cytes from ALS patients [164]. Furthermore, downregula-
tion of miR-155 in the CNS of SOD1G93A mice using the
antisense oligonucleotide anti-miR-155 resulted in signi-
ficant extension of survival by 10 days and disease dura-
tion by 15 days (38%) in comparison with scrambled oligo-
nucleotide control-treated mice [163]. Given the important
proinflammatory function of miR-155 [44–7] and the fact
that miR-155 has been found to be upregulated in AD
CSF and neocortex ECF [43], it is possible that the elev-
ated miR-155 levels in ALS reflect the ongoing neuroin-
flammation. As the administration of anti-miR-155 caused
global derepression of targets in peritoneal macrophages
after intraperitoneal treatment with lipopolysaccharide in
mice, and since the anti-sense oligonucleotides were detec-
ted in CNS microglia upon intraventricular administration
[163], the significant extension of survival of SOD1G93A
mice may be associated with reduced non-cell autonomous
neuronal toxicity of glial cells [165]. As miR-23a, which is
overexpressed in the skeletal muscle of ALS patients, was
found to repress PGC-1α translation in a 3′UTR depend-
ent manner both in vitro and in mice, leading to skeletal
muscle mitochondrial dysfunction in ALS [151], inhibition
of miR-23a in skeletal muscle may represent potential ther-
apy in ALS.
miRNAs as biomarkers in ALS/FTD
Microarray screening of 911 human miRNAs in leucocytes
obtained from 8 sporadic ALS patients and 12 healthy
controls revealed that miR-451, miR-1275, miR-328-5P,
miR-638, miR-149 and miR-665 were downregulated
across different gender groups, as well as in all examined
samples. Importantly, qPCR analysis of miR-338-3p in 14
sporadic ALS patients and 14 controls confirmed the spe-
cific miR-338-3p upregulation in leucocytes of all ALS pa-
tients, suggesting that this miRNA could represent an in-
valuable marker for ALS that could offer early diagnosis
through a blood test [167].
A qPCR screen of TDP-43 binding miRNAs in human ser-
um and CSF found that out of the 9 recently discovered
TDP-43 binding miRNAs, miR-132-5p, miR-132-3p and
miR-143-3p were significantly downregulated, and
miR-143-5p and miR-574-5p were significantly upregu-
lated in serum and CSF of matched sporadic ALS patients
suggesting a systemic epigenetic dysregulation in ALS
[168].
Huntington’s disease
Huntington's disease (HD) is a fatal inherited autosomal
dominant neurodegenerative disorder caused by an expan-
sion of the CAG repeat localised in the first exon of the
huntingtin gene (HTT or IT-15) [169]. Expression of the
mutant huntingtin protein with an expanded poly-glutam-
ine tract [169] induces progressive neurodegenerative
changes in the whole brain, with the main pathology ob-
served in the striatum, cortex [170] and white matter [171,
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172], consequently leading to progressive motor dysfunc-
tion, cognitive decline and psychiatric disturbance [173].
Prevalence of the mutation/disease is about 4–10 per
100 000 in populations of Western European and North
American descent, with many more at risk of the disease
[170, 174]. CAG repeats longer than 40 are associated with
practically full penetrance by the age of 65 years [173,
175]. Longer CAG repeats predict earlier onset of the dis-
ease [175], accounting for up to 50%–70% of variance in
age of onset [173] with the remaining variance most likely
to be attributed to modifying genes (40% of remainder) and
the environment (60% of remainder) [176].
Most HD patients have expansions ranging from 40‒55
CAG repeats [170, 175], leading to the onset of the disease
symptoms in middle age (40 years in average), whereas ju-
venile onset (under the age of 20) is associated with CAG
repeats of 60 or longer [175]. The disease progresses over
15–20 years from onset and culminates in death [177].
REST-induced mRNA and miRNA transcriptome
disruption in Huntington’s disease
It has long been known that the mutant huntingtin disrupts
transcription as wild-type huntingtin sequesters the avail-
able REST/NRSF (RE1-silencing transcription factor; aka
neuronal restrictive silencing factor) in the cytoplasm pre-
venting it from forming the nuclear co-repressor complex
at the RE1/NRSE (repressor element 1; aka neuron restrict-
ive silencer element) nuclear site and allowing gene tran-
scription of neuronal genes, while the mutant huntingtin
does not [178]. It was therefore hypothesised that in the
CNS, huntingtin may represent a general coordinator of
neuronal gene transcription [178, 179]. Further research re-
vealed that REST transcriptionally represses the miRNA
family that includes miR-124a, one of the most common
and highly expressed CNS miRNAs. [180]. During neur-
onal differentiation, similar to canonical REST-regulated
genes, miR-124a expression is only allowed when REST
dissociates from its chromatin binding sites. Diminishing
miR-124a activity in mature neurons resulted in specific
increase of non-neuronal genes, further demonstrating the
neuronal specificity of miR-124a [180].
REST-regulated miRNAs in HD thus became widely re-
searched. In the pivotal search for miRNA dysregulation
in HD, REST binding sites [181] were compared with the
positions of known miRNA genes [182], which identified
17 possible miRNA targets of REST, including 13 mouse
orthologous miRNA-RE1 pairs [181]. Chromatin immun-
oprecipitation assay confirmed that the identified miRNA
RE1s are indeed capable of interaction with REST both
in vitro and in vivo. MiR-132 was found to be downregu-
lated in brains of both human HD patients and R6/2 mice,
the most commonly used model of HD expressing the hu-
man HTT exon 1 with 144 CAG repeats under the con-
trol of the human HTT promoter. Other miRNAs, however,
showed divergent results, such as miR-29a, which is signi-
ficantly upregulated in HD patients, but downregulated in
R6/2 mice and miR-330, which was significantly upregu-
lated in HD samples, but undetectable in R6/2 mice [181].
These data demonstrate that apparent differences could be
expected across the samples of different origin, i.e. human
HD and animal HD models that apparent differences could
be expected across the samples of different origin (i.e., hu-
man HD patients and animal HD models).
Changes of miRNA expression levels correspond to
target gene expression in Hungtington’s disease and
correlate with disease progression
Nevertheless, further research brought significant function-
al discoveries of how miRNAs are involved in the patho-
genesis of HD. REST-regulated miRNAs miR-9, miR-9*,
miR-29b, miR-124a (all downregulated), and miR-132 (up-
regulated) differ significantly with increasing HD grade as
detected with qPCR of human brain samples from Brod-
mann area 4 [135]. Both miR-196a (six-fold) and miR-486
(three-fold) were also found to be significantly upregulated
in HD1 grade samples. Importantly, this study revealed that
miR-9 targets REST and miR-9* targets CoREST, the com-
ponents of the REST repressor complex [135]. The au-
thors explained the conflict of their results with those of
Johnson et al. [181] by the fact that while they analysed
mature miRNAs, Johnson et al. used precursor miRNAs
[135]. In an in-vitro study comparing the miRNAs expres-
sion in HdH109/109 and Hdh7/7 cells with qPCR, Soldati et al.
[183] confirmed that many HD-dysregulated miRNAs are
directly repressed by elevated levels of REST, including
miR-9, miR-9*, miR-29b, miR-124, miR-132, miR-135b
which is consistent with previous findings [135, 181], but
also previously not reported miR-137 and miR-153, as well
as REST-indirectly controlled miR-222. Most importantly,
they confirmed that impairment in the widespread regula-
tion of miRNA expression by REST results in increased
gene expression of miRNA targets in HD as they show that,
for instance, Ak2, Elov1 and Ctdsp2 (miR-124 targets), are
upregulated in Hdh109/109 cells [183].
Similarly, in one of the best large animal models for HD,
the transgenic HD monkey (rhesus macaque), as well as
in human HD brains, miR-128a was found to be signific-
antly downregulated. It has been shown with a luciferase
assay that miR-128a regulates the HD canonical signalling
genes HIP-1, HTT, SP-1 and GRM5 [184]. Microarray ana-
lysis of 352 rhesus miRNAs led to detection of 11 dysreg-
ulated miRNAs in the frontal cortex. Four miRNAs with
significant target association to the HD canonical pathway
were further analysed with qPCR, which validated signific-
ant downregulation of miR-181c, miR-128a and miR-133c,
and significant upregulation of miR-194 [184]. The same
group has also previously discovered that miR-196a indir-
ectly regulates the expression and aggregation of mutant
huntingtin both in vitro and in vivo, involving miR-196a-
induced alteration of ubiquitin-proteasome system, gliosis,
and the cyclic AMP response element-binding protein
(CREB) pathway [185].
Regulation of miRNA by p53 in Huntington’s disease
Using frontal cortex and striatal samples isolated from HD
patient brains and appropriate controls, REST-regulated, as
well as REST-independent miRNAs, were found to be dys-
regulated by means of next generation sequencing [16].
The latter approach revealed length and sequence hetero-
geneity for almost all miRNAs (isomiRs) and that the
mechanisms governing the expression of identified
miRNAs and their corresponding isomiRs are mostly par-
Review article: Medical intelligence Swiss Med Wkly. 2015;145:w14192
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 10 of 22
allel. Importantly, it was also discovered that the promoter
region of the downregulated miRNAs in frontal cortex har-
bour significantly more p53 regulatory motifs [16] and p53
was previously shown to regulate multiple miRNAs [186].
Mutant huntingtin binds P53 and induces its overexpres-
sion [187]. In addition, p53 regulates most miRNAs among
all transcription factors studied and this can be explained
by its overexpression in HD [188]. Therefore, p53 may
contribute to the widespread downregulation of miRNA in
HD [16, 188].
Chromosomal clusters display similar regulation in
Huntington’s disease
Significant upregulation of five miRNAs (miR-10b-5p,
miR-196a-5p, miR-196b-5p, miR-615-3p and
miR-1247-5p) has been identified with next generation se-
quencing of samples from HD and normal control brains
(prefrontal cortex [Brodmann area 9]) and the differential
expression of these miRNAs was further validated with
qPCR. Interestingly, miR-10b-5p, miR-196a-5p,
miR-196b-5p and miR-615- 3p are strongly related to Hox
cluster genes [189]. Moreover, it was found that miRNA
in chromosomal clusters exhibited similar expression pat-
terns in HD; for example, let-7a, let-7c, let-7d and let-7e
were all downregulated in HD frontal cortex and striatum
and miR-30a, miR-30b, miR-30c and miR-30e were upreg-
ulated in the same tissues [16]. Additionally, miR-10b-5p,
miR-196a-5p, miR-196b-5p and miR-615-3p, which are
miRNAs strongly related to Hox cluster genes, were all
found to be significantly upregulated in prefrontal cortex of
HD patients [189]. Lastly, expression of IsomiRs and the
corresponding miRNAs are in most cases parallel [16].
miRNA regulation by stress granules
The interesting hypothesis that mutant huntingtin impairs
miRNA-mediated mRNA regulation and local translation,
via its accumulation into stress granules together with argo-
naute 2, an RNA-induced silencing complex (RISC) com-
ponent, which is required for RNA-mediated gene silen-
cing, has been proposed [189–91]. TDP-43 and FUS ac-
cumulate into stress granules as a normal physiological
response to stress [192, 193] and it has been hypothesised
that the association of TDP-43 and FUS/TLS with stress
granules may be an initiating event which, following
chronic stress, eventually leads to irreversible pathological
aggregation [126]. Taken together, the above highlight the
possibility that pathological accumulation followed by co-
aggregation of these proteins with RISC and/or Drosha and
Dicer complexes and multiple mRNAs could represent a
common pathological mechanism in both ALS/FTD spec-
trum diseases and HD.
Dysregulation of miR-196a associates with clinical
features of Huntington’s disease and represents
potential therapeutic agent in Huntington’s disease
Next generation sequencing data of a relatively large num-
ber of patient samples allowed association studies of up-
regulated miRNAs with clinical features of HD. It was dis-
covered that CAG repeat size correlates with miR-10b-5p
and miR-196a-5p, age of motor dysfunction onset with
miR-10b-5p, miR-196a-5p and miR-196b-5p, and age at
death with miR-10b-5p and miR-615-3p [189]. Previoulsy,
miR-196a had been found to be significantly overexpressed
in HD1 brains [135] and in mutant huntingtin transfected
NT2-derived neurons [166], and its overexpression resul-
ted in downregulation of mutant huntingtin in human iPSC-
derived HD neurons and in an HD mouse model [185]. It
is, therefore, possible that increased miR-196a expression
is an adaptive response promoting neuronal survival [189]
but that its endogenous activation in HD is not sufficient to
ameliorate the HD pathology [185]. However, overexpres-
sion of miR-196a may represent a potential therapeutic ap-
proach [185, 189].
miRNAs as biomarkers in HD
In order for miRNAs to become valuable biomarkers of
HD onset and/or progression, they obviously need to be de-
tectable and adequately stable. Importantly, human plasma
miRNAs were reported to withstand repeated freeze-thaw
cycles and, in only small volumes of plasma, p53-regulated
miR-34b was found to be elevated in premanifest HD pa-
tients as detected with qPCR [166]. An earlier study of HD
patient-derived whole blood identified multiple signific-
antly upregulated mRNAs compared with controls [194],
but this finding could not be replicated [195]. Next genera-
tion sequencing of plasma samples with further qPCR val-
idation of miR-34b expression obtained from a large HD
patient cohort is therefore absolutely necessary.
miRNAs in muscle dystrophy
The first evidence for an important role of miRNAs in
mammalian myogenesis was shown for the paradigm of
myoblast to myotube conversion [196–8]. Subsequently,
there was an increasing interest for the regulation of
miRNAs in muscle diseases. Muscular dystrophies are a
heterogenous class of >30 different inherited myopathies
[199] that were an obvious start for this search. They show
a high cycling of muscle degeneration and regeneration,
satellite cell proliferation, inflammation, adipocyte infilt-
ration and fibrosis, giving many possibilities for miRNA
regulation in diverse cell types. Duchenne muscular dys-
trophy (DMD) is the most prevalent and most severe of the
muscular dystrophies, affecting about 1 in 3 500 live males.
This X-linked recessive disease is caused by mutations in
the dystrophin gene, which encodes for a large protein that
connects the extracellular matrix with the cytoskeleton of
muscle. This bridging function is thought to be important
to stabilise the sarcolemma.
The mdx mouse – a mouse model for muscle dystrophy
The first investigations of altered miRNA expression in
dystrophic skeletal muscle were performed in the most
commonly applied mouse model for muscle dystrophy, the
mdx mouse. These mice carry a stop codon in the dystroph-
in gene, mimicking the human situation, but the disease
is rather mild in the mice possibly due to a higher regen-
erative capacity compared with humans. McCarthy et al.
analysed with qPCR the expression of three muscle-spe-
cific miRNAs, miR-206, miR-1 and mi-133, and found a
four- to five-fold increase of miR-206 in diaphragm with
no major regulation in soleus or plantaris muscles [200].
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Muscle-specific miR-1 and miR-133a showed no major
regulation in any of the three muscle groups. The induction
of miR-206 was most likely posttranscriptional since the
primary transcript of this miRNA, pri-miR-206, was also
upregulated. The isolated induction of miR-206 in the dia-
phragm was not completely surprising since the diaphragm
represents the most severely affected muscle group in this
mouse model. However, it was later shown that miR-206
is induced, while miR-1 is downregulated, also in other
muscle groups of the mdx mice [203].
Regulation of miRNAs in patients with muscle
dystrophy
Using miRNA microarrays, Eisenberg et al. identified no
fewer than 151 miRNAs that are upregulated and 28 that
are downregulated in 10 major muscle disorders [201]. In-
terestingly, with the exception of five miRNAs, the ex-
pression of these miRNAs was specific to individual dis-
ease groups. A significant correlation between miRNAs
and their targets was observed in DMD patients and pa-
tients with Miyoshi myopathy, indicating that miRNAs
could be also functionally relevant in muscle diseases.
Messenger RNA ‒miRNA modules regulated in both
muscle diseases were extracellular matrix processes and
cytoskeletal organisation, indicating that these could be
common functional clusters in dystrophic muscles regu-
lated by miRNAs. Using qPCR, Greco et al. compared
the levels of 250 adductor muscle miRNAs in mdx versus
wild-type mice and identified 36 miRNAs that were reg-
ulated significantly [202]. Importantly, 11 miRNAs were
identified as a common miRNA signature between mdx
mice and DMD patients including miR-1, which was about
three-fold downregulated, and miR-206, which was four-
to nine-fold upregulated. Regulation of only three miRNAs
was overlapping with the report from Eisenberg et al
(miR-222, miR-335, miR-29c). Cacciarelli et al. ran low-
density qPCR arrays on mdx and wild-type muscles, and
detected as the most prominent changes the downregula-
tion of miR-1, miR-133a, miR-29c and miR-30 and the in-
duction of miR-206 [203]. Downregulation of miR-1 and
miR-29c was attributed to transcriptional repression by his-
tone deacetylase 2 (HDAC2). Importantly, this study also
addressed the intramuscular localisation of miR-1 and
miR-206. Localisation of miR-206 was restricted to newly-
formed regenerating myofibres characterised by a central-
ised nucleus, while miR-1 showed intense signals in all ma-
ture fibres. These results indicated that increased expres-
sion of miR-206 is caused by the presence of newly formed
fibres, while the downregulation of miR-1 is the conse-
quence of a decrease in adult myofibres. The same group
later discovered that the muscle-specific miRNAs are re-
leased into the blood of Duchenne patients and that their
levels correlated with disease severity [204]. Cacchiarelli
et al. also identified a nonmuscle specific miRNA, miR-31,
that colocalised with miR-206 in regenerating fibres and
was also strongly induced in mdx muscles and DMD pa-
tient samples [205].
The miR-206 knockout mouse
The first evidence for a functional role of a regulated
miRNA in dystrophic muscles in vivo came from Liu et
al., who deleted miR-206 in mice during embryonic de-
velopment and crossed these mutants with the mdx mice
[206]. The loss of miR-206 resulted in a more severe dys-
trophic phenotype in the mdx mice with creatine kinase
activity, a marker of muscle damage, being eight-fold high-
er in the mutants than in the control mice. These results
indicate that the upregulation of miR-206 in dystrophic
muscle could serve as a protection mechanism to facilitate
the formation of new fibres during muscle regeneration.
Interestingly, miR-206 was also found to be significantly
upregulated in skeletal muscles of the SOD1G93A mouse
model of ALS [150, 152], as well as in skeletal muscles
of ALS patients [151]. It has been shown that miR-206
promotes compensatory mechanisms that lead to regener-
ation of neuromuscular junctions, partially reinnervating
muscles and resulting in delayed disease progression in the
SOD1G93A mouse model [150], further supporting the idea
that upregulation of miR-206 in regenerating muscle fibres
is protective and its overexpression in skeletal muscles of
ALS patients could delay muscle weakness and possibly
slow down disease progression.
Potential for miRNAs as biomarkers in muscle
dystrophy
Together these studies provide evidence that miRNAs are
regulated in dystrophic muscles in animal models and pa-
tients. The overlap of regulated miRNAs between these
studies is rather small, probably as a result of the different
muscle groups that had been investigated or different tech-
niques with which miRNAs were quantified (oligonuc-
leotide arrays, qPCR, northern blotting). However, down-
regulation of miR-1 and upregulation of miR-206 have
been repeatedly confirmed. These studies also demonstrate
that miRNAs in muscle tissue or serum could be interesting
markers for disease severity in muscle dystrophy. miRNAs
in serum could be envisioned as biomarkers to monitor
noninvasively clinical trials or to identify patients, who
would benefit from interventions. The example of miR-206
highlights the idea that miRNAs could also serve as new
therapeutic targets for muscle diseases.
Role of miRNA in cardiovascular
disease
Several miRNAs have been identified as critical modu-
lators of cardiovascular development and pathophysiology
[207]. The important role of miRNAs in the cardiovascular
system has provided novel perspectives on the patho-
physiology of cardiovascular disease and has revealed in-
teresting potential novel therapeutic targets [208, 209].
miRNA and cardiac function
Cardiac deletion of enzymes required in the biogenesis
of miRNAs, such as Dicer, resulted in dilated cardiomy-
opathy and premature lethality, supporting a critical role of
miRNA biogenesis for cardiac function and structure [210,
211]. By using a high-throughput functional screening ap-
proach, Wahlquist et al. have recently identified miR-25 as
a potent regulator of calcium uptake kinetics in cardiomyo-
cytes in vitro (out of 875 miRNAs tested) and observed
that miR-25 was upregulated in heart failure, in both mice
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and humans [212]. Moreover, overexpression of miR-25
in vivo resulted in a reduced contractile cardiac function,
whereas injection of an antisense oligonucleotide against
miR-25 (anti-miR-25) markedly prevented progression of
established heart failure in a mouse model and improved
cardiac function and survival [212]. Furthermore, miR-34a
was reported to be induced in ageing hearts and in-vivo si-
lencing of miR-34a reduced age-associated cardiomyocyte
cell death, cardiac fibrosis and promoted recovery of cardi-
ac function after myocardial infarction [213]. Interestingly,
miR-34a is upregulated in blood mononuclear cells of pa-
tients with sporadic AD [54], which may also represent a
consequence of aging.
miRNA in cardiac development and stem cells
Dynamic regulation of miRNA is involved in develop-
mental biology, for example, differentiation of embryonic
stem cells towards a cardiomyocyte fate, and in-vitro stud-
ies have shown that miR-1, together with miR-499, are up-
regulated in the differentiation of human embryonic stem
cells and cardiac progenitor cells toward cardiomyocytes.
[214, 215] Overexpression of these miRNAs enhances dif-
ferentiation toward a cardiomyocyte fate [214, 215].
miRNA and atherosclerotic vascular disease
Several recent reports have revealed that the human sterol-
regulatory-element-binding-protein genes SREBF1 and
SREBF2 harbour two intronic miRNAs, miR-33b and
miR-33a, respectively, that modulate homeostasis of cho-
lesterol and triglycerides, which are critical for the ather-
osclerotic disease process [209, 216]. Anti-miR33-treated
mice showed reduced atherosclerotic plaque size and lipid
content and decreased inflammatory gene expression
[217].
Pharmacological inhibition of miR-33 using a subcu-
taneously injected, locked nucleic acid (LNA)-modified
anti-miR in a nonhuman primate metabolic disease model
lowered very low-density lipoprotein tryglycerides [218]
and resulted in limited atherosclerosis progression in a
mouse model of atherosclerosis [217].
We and others have observed a critical role of miR-126,
which is particularly expressed in endothelial cells, for
ischaemia-induced neovascularisation, for example, after
myocardial infarction and in atherosclerotic vascular dis-
ease [219, 220]. In patients with chronic heart failure,
miR-126 levels were markedly reduced in circulating en-
dothelial repair-promoting cells. Moreover, administration
of miR-126 promoted endothelial cell proliferation at pre-
dilection sites and reduced experimental atherosclerosis,
suggesting that miR-126 may represent a potential novel
therapeutic target to prevent progression of atherosclerotic
vascular disease, the main cause of death in developed
countries [220]. Notably, miR-126 limits leucocyte adher-
ence to endothelial cells, at least in part by suppressing
endothelial vascular cell adhesion molecule 1 (VCAM-1)
expression, suggesting that miR-126 may limit vascular in-
flammation [221].
Role of miRNA in the pathogenesis of
inflammation
MiRNA in autoimmune and inflammatory diseases
The immune system protects the organism from attack by
microorganisms such as bacteria, viruses and parasites.
Whereas the local inflammation at the site of infection and
elimination of infected cells is necessary for defense of the
individual, failure to control inflammation once microor-
ganisms are cleared can have devastating consequences. It
is, therefore, important to understand the molecular mech-
anisms regulating immune reactions and their defects in the
various autoimmune diseases. The recognition of noncod-
ing RNAs, in particular miRNAs, as a new principle of
regulation of gene-expression, has been a major advance.
Dysregulation of miRNA has been linked to cancer, cardi-
ovascular, infectious and autoimmune diseases. Important
pathways in the innate as well as the adaptive immune sys-
tem are under control of miRNAs. As one miRNA has a
multitude of targets and acts in a tissue specific way, the
complexity of this regulatory system is considerable. In-
creasing evidence indicates that the expression patterns of
miRNAs are dysregulated in a variety of autoimmune dis-
eases. Whereas many different miRNAs have been repor-
ted to be either up- or downregulated in specific autoim-
mune diseases, an impact of these expression changes on
the development of autoimmune diseases has been demon-
strated only in a few instances so far.
Figure 3
Regulatory role of miR-146 and miR-155 on inflammation in
activated synovial fibroblasts of patients with rheumatoid arthritis
(A) and on type I interferon production in PBMC of patients with
SLE (B). (A) Activation of synovial fibroblasts by endogenous Toll-
like receptor (TLR) ligands or interleukin 1 (IL-1) initiates a
signalling cascade via nuclear factor kappa B (NF-κB) resulting in
expression of proinflammatory cytokines, such as tumour necrosis
factor alpha (TNF-α). Overexpression of TNF-α is a hallmark of
rheumatoid arthritis. In activated synovial fibroblasts miR-155
expression is induced, further enhancing TNF-α production. In
contrast, miR-146 has a modulatory role by inhibiting the signalling
molecules interleukin 1 associated receptor kinase 1 (IRAK1) and
TNF-receptor accessory factor 6 (TRAF 6). (B) Regulatory role of
miR-146 in SLE PBMC. In contrast to the overexpression of
miR-146 in RA, in SLE miR-146 levels are decreased, resulting in
an increased activation of IRF-5 and expression of type 1
interferon.
IRF-5 = interferon regulatory factor 5; PBMC = peripheral blood
mononuclear cells; RA = rheumatoid arthritis; SLE = systemic lupus
erythemotosus
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Rheumatoid arthritis
First reports on miRNA expression in rheumatoid arthritis
appeared in 2008, describing upregulation of miR-155 and
-146 in the rheumatoid synovium [222, 223]. Expression
of miR-155 was shown to be induced by lipopolysacchar-
ide and polyinosinic:polycytidylic acid (poly-I:C) in a
MyD88-dependent fashion [224]. Macrophages overex-
pressing miR-155-produced significantly more tumour
necrosis factor-α (TNF-α) and miR-155 transgenic mice
showed increased sensitivity to lipopolysaccharide-in-
duced septic shock, whereas miR-155 deficient mice failed
to produce TNF-α [45, 46]. Also, miR-155 deficient mice
were shown to be resistant to collagen-induced arthritis,
whereby the generation of autoreactive B and T cells was
prevented. The example of miR-155 demonstrates that a
single miRNA can have a profound impact on the de-
velopment of an autoimmune disease (fig. 3). Contrary to
miR-155, miR-146 was shown to have an anti-inflammat-
ory role. By targeting IRAK-1 and TRAF-6 miR-146 is
a negative regulator of NF-κB activation. Accordingly,
miR-146 deficient mice develop a fatal immune-mediated
disease and tumours in lymphoid organs [47]. Administra-
tion of miR-146 in mice with established collagen-induced
arthritis reduced bone destruction, but had no significant
effect on inflammation [44]. Interestingly, a polymorphism
in the 3’UTR of the IRAK-1 gene, a target of miR-146,
is associated with the susceptibility to rheumatoid arthritis
[225]. A number of additional miRNAs have been shown
to be dysregulated in rheumatoid arthritis synovial cells.
Most of these studies are however mainly descriptive and
provide limited information on the functional impact of the
miRNA as well as the regulation of their expression.
Systemic lupus erythematosus
Studies of miRNA in systemic lupus erythematosus (SLE)
have focused primarily on miR-146a. In peripheral blood
mononuclear cells of pateints with SLE, miR-146 was
found to be downregulated, and expression of miR-146
was inversely correlated with the disease activity. Over-
expression of miR-146 reduced type I interferon produc-
tion by targeting IRF-5 and STAT-1 [226]. Therefore it was
proposed that deficient miR-146 expression may be one
of the causal factors of type I interferon pathway activa-
tion, characteristically seen in SLE. In support of this hy-
pothesis, a functional promoter variant of miR-146a was
found to confer risk for developing SLE [227]. Treatment
of lupus-prone BXSB mice with virus-like particles con-
taining miR-146 significantly reduced autoantibody pro-
duction and could ameliorate SLE progression [228]. Ana-
lyses of expression profiles of miRNA in kidney tissue of
patients with SLE revealed that miRNA expression is or-
gan and cell-type specific, as expression differed from peri-
pheral blood mononuclear cells of SLE patients. In con-
trast to the findings in peripheral blood mononuclear cells,
miR-146a was found increased in glomerular tissue. In ro-
dent models of SLE, various additional miRNAs have been
found to contribute to disease. Both miR-21 and miR-214
were shown to be upregulated in renal tissue and upon
stimulation of rat epithelial cells with transforming growth
factor-β (TGF-β) in vitro. Inhibition of TGF-β signalling
resulted in a downregulation of miR-21 and -214 and in-
hibition of epithelial-mesenchymal transition and collagen
type I production. This suggests that TGF-β-induced
miR-21 and miR-214 expression may contribute to ex-
tracellular matrix production and mesangial proliferative
glomerulonephritis [229].
miR-21 was also found to be upregulated in systemic scler-
osis skin fibroblasts and correlated with disease activity. A
profibrotic effect of TGF-β-induced miR21 was postulated
by negatively regulating its target Smad7 [230].
Interestingly, it has been shown that patients with connect-
ive tissue diseases may produce antibodies against proteins
of the miRNA pathway, which localise in the cytoplasm in
the so-called GW-bodies. Anti-GWB-antibodies have been
identified in patients with SLE, Sjogren’s syndrome and
rheumatoid arthritis and seem to be associated with neuro-
logical symptoms [231]. The functional relevance of these
autoantibodies is still unclear.
Inflammatory bowel disease
In 2008 alterations in miRNA expression in inflammatory
bowel disease were described for the first time [232]. Ana-
lyses of miRNA expression profiles of intestinal biopsy tis-
sue as well as of peripheral blood mononuclear cells have
revealed distinct profiles in ulcerative colitis and Crohn’s
disease. However, information on the functional impact of
these miRNAs is still lacking to a large extent. Decreased
levels of miR-7 in inflamed colonic tissue in Crohn’s dis-
ease have been reported to correlate with upregulated ex-
pression of CD98, its target, which controls proliferation
and differentiation of enterocytes [233]. A recent study has
shown overexpression of miR-196 in intestinal epithelial
cells in inflamed Crohn’s disease. Interestingly, miR-196
was found to bind to the protective variant of the immunity-
related GTPase M (IRGM) but not a mutated IRGM which
was shown to be highly associated with Crohn’s disease in
European populations [234]. Similarly, it has been demon-
strated that a variant of the IL-23R gene, highly associated
with inflammatory bowel disease, results in the loss of a
binding site for the miRNAs let-7e and let-7f, with in-
creased expression of IL-23R in vitro. These results
demonstrate possible links of miRNA dysregulation and
pathogenesis of inflammatory bowel disease [235].
In summary, in autoimmune and autoinflammatory dis-
eases a dysregulation of miRNA expression has been
demonstrated which can have a profound impact on the
pathogenesis of these diseases. Therefore, miRNAs are at-
tractive targets for immunomodulatory therapeutic inter-
vention. Moreover, miRNAs hold great promise as markers
of disease activity and prognosis and to guide therapeutic
intervention (for review [236]).
Outlook on translation of miRNA
research into the clinics
Clearly, basic research provided us with breakthrough dis-
coveries of miRNA biogenesis and the crucial function
of miRNAs as genome regulators. Animal research using
various mouse disease models was an important step that
revealed that miRNAs indeed do change in disease. Later,
it was recognised that changes in miRNA levels could be
either a consequence or a direct trigger of the disease and it
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is now well established that changes of levels in numerous
miRNAs reflect the disease onset and progress, and that
could even be used for presymptomatic diagnosis and pro-
gnosis. Moreover, targeting the dysregulated miRNAs rep-
resents a new and very potent therapeutic intervention.
It is, however, important to point out that the results ob-
tained from animal models are very often not directly rep-
licated in the clinic. This may be owing to the inherent vari-
ability in human samples and it is obvious that all screening
conditions (including sample source, size and preparation,
screening techniques, data collection, analysis, validation
and interpretation) need to be standardised across all pa-
tients and study sites in order for the miRNAs to become
reliable disease biomarkers.
Unbiased screening using next generation RNA sequencing
enables us to screen all known miRNAs, thus eliminating
the possibility that the most affected miRNAs would be
missed. Finally, given the large number of miRNAs, each
regulating hundreds of mRNAs, it is possible that multiple
miRNAs will become markers of certain disease processes
rather than a single miRNA. Once such data are available,
algorithms that would compare them across different pa-
tient groups and/or diseases may reveal common molecular
mechanisms that would enable us to identify potential
asymptomatic, yet already ongoing, pathological processes
that may currently be missed during routine diagnostic pro-
cedures. This could lead to early therapeutic intervention
that may involve direct targeting of the known, pathologic-
ally dysregulated miRNA(s), as well as other targets. We
foresee that in the future, all this will be feasible from a
single drop of body fluid, such as blood or CSF.
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Figures (large format)
Figure 1: miRNA alternations in neurodegenerative diseases. Numerous alternations in miRNA biogenesis and function were found to
contribute to the pathogenesis of several neurodegenerative diseases including: (A) In HD, miRNA transcription is disturbed as mutant
huntingtin does not bind REST (which is normally bound to wild-type huntingtin), allowing the formation of NRSE thus repressing the
transcription of neuronal miRNAs [135, 181, 183]. Mutant huntingtin also binds to p53 dysregulating p53-mediated transcription of miRNAs [16,
188]. (B) Downregulation of miR-124 has been found to cause missplicing of APP in AD [42]. (C) Ago has been found to be sequestered by
mutant huntingtin and accumulated into stress granules in HD suggesting impaired miRNA-mediated mRNA regulation [189–191]. Interestingly,
mutant LRRK2 also interacts with Ago, impairing mRNA regulation by miRNAs [72]. (D) Expression of APP and BACE1 in AD [37–41, 48–52]
and SNCS and LRRK2 in PD [71-73] has been described to be specifically affected by their regulating miRNA(s) that are disturbed in these
diseases. (E) Non-cell autonomous neurodegeneration is now well recognized in ALS and miR-155 seems to play a major role in the pathologic
microgliosis [43, 163, 165].
3’UTR = 3’ untranslated region; AD = Alzheimer’s disease; ALS = amyotrophic lateral sclerosis; APP = amyloid precursor protein; BACE-1 = β-
secretase 1; HD = Huntington’s disease; HTT = huntingtin gene; LRRK2= leucine-rich repeat kinase 2; miRNA = microRNA; mRNA =
messenger RNA; NRSE = neuron restrictive silencer element; PD = Parkinson’s disease; pri-miRNA = primary miRNA; REST = RE1-silencing
transcription factor; RISC = RNA-induced silencing complex
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Figure 2: Proposed new strategies for high throughput small RNA screens to discover cell signalling mechanisms and novel therapeutic target
for prion disease.
HTS = high throughput screening; sgRNA = single guide RNA; shRNA = short hairpin RNA; siRNA = small interfering RNA
Figure 3: Regulatory role of miR-146 and miR-155 on inflammation in activated synovial fibroblasts of patients with rheumatoid arthritis (A) and
on type I interferon production in PBMC of patients with SLE (B). (A) Activation of synovial fibroblasts by endogenous Toll-like receptor (TLR)
ligands or interleukin 1 (IL-1) initiates a signalling cascade via nuclear factor kappa B (NF-κB) resulting in expression of proinflammatory
cytokines, such as tumour necrosis factor alpha (TNF-α). Overexpression of TNF-α is a hallmark of rheumatoid arthritis. In activated synovial
fibroblasts miR-155 expression is induced, further enhancing TNF-α production. In contrast, miR-146 has a modulatory role by inhibiting the
signalling molecules interleukin 1 associated receptor kinase 1 (IRAK1) and TNF-receptor accessory factor 6 (TRAF 6). (B) Regulatory role of
miR-146 in SLE PBMC. In contrast to the overexpression of miR-146 in RA, in SLE miR-146 levels are decreased, resulting in an increased
activation of IRF-5 and expression of type 1 interferon.
IRF-5 = interferon regulatory factor 5; PBMC = peripheral blood mononuclear cells; RA = rheumatoid arthritis; SLE = systemic lupus
erythemotosus
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